You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAntipyrine
Accession NumberDB01435
TypeSmall Molecule
GroupsApproved
DescriptionAn analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Structure
Thumb
Synonyms
1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one
2,3-Dimethyl-1-phenyl-5-pyrazolone
Analgesine
Antipyrine
Fenazon
Fenazona
Phenazon
Phenazone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Acella Antipyrine and Benzocaine OticACELLA PHARMACEUTICALS
Antidouleurs RezallProduits Francais Labs Inc.
Antipyrine and BenzocaineRebel Distributors Corp
Antipyrine and Benzocaine OticACELLA PHARMACEUTICALS
AuralganPaladin Labs Inc
Auralgan EardropsWyeth Canada
Auralgan SolutionWyeth Consumer Healthcare Inc.
Aurax OticAcella Pharmaceuticals, LLC
AurodexMajor Pharmaceuticals
Formule L2Herbages Naturbec LtÉe.
Oti CalProduits Francais Labs Inc.
Otic Care Antipyrine and BenzocainePure Tek Corporation
OtozinAllegis Pharmaceuticals, LLC
SaltsNot Available
Categories
UNIIT3CHA1B51H
CAS number60-80-0
WeightAverage: 188.2258
Monoisotopic: 188.094963016
Chemical FormulaC11H12N2O
InChI KeyInChIKey=VEQOALNAAJBPNY-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
IUPAC Name
1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one
SMILES
CN1N(C(=O)C=C1C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassPyrazoles
Direct ParentPhenylpyrazoles
Alternative Parents
Substituents
  • Phenylpyrazole
  • Benzenoid
  • Pyrazolinone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationAntipyrine is an analgesic often used to test effects of other drugs on liver enzymes..
PharmacodynamicsAntipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Mechanism of actionAntipyrine is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Antipyrine
NorantipyrineDetails
Antipyrine
3-HydroxymethylantipyrineDetails
Antipyrine
4-HydroxyantipyrineDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Antipyrine Action PathwayDrug actionSMP00692
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9931
Caco-2 permeable+0.8273
P-glycoprotein substrateNon-substrate0.8995
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8737
Renal organic cation transporterNon-inhibitor0.8837
CYP450 2C9 substrateNon-substrate0.6871
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6459
CYP450 1A2 substrateNon-inhibitor0.8617
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9444
CYP450 2C19 inhibitorNon-inhibitor0.9533
CYP450 3A4 inhibitorNon-inhibitor0.9615
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7357
Ames testNon AMES toxic0.9261
CarcinogenicityNon-carcinogens0.9202
BiodegradationNot ready biodegradable0.9761
Rat acute toxicity2.0746 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9816
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquid
Liquidtopical
Dropsotic
Solutionotic
Solutionauricular (otic)
Liquidoral
Drops
Solutiontopical
Prices
Unit descriptionCostUnit
Auralgan ear drops13.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114 °CPhysProp
boiling point319 °CPhysProp
water solubility5.19E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.38HANSCH,C ET AL. (1995)
Caco2 permeability-4.55ADME Research, USCD
pKa1.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility47.4 mg/mLALOGPS
logP1.18ALOGPS
logP1.22ChemAxon
logS-0.6ALOGPS
pKa (Strongest Basic)0.37ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability20.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.41 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Andreas Burgard, “Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use.” U.S. Patent US20030008865, issued January 09, 2003.

US20030008865
General ReferencesNot Available
External Links
ATC CodesN02BB51N02BB01N02BB71S02DA03
AHFS Codes
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
AbciximabAntipyrine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Antipyrine can be increased when it is combined with Abiraterone.
AcebutololAntipyrine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aceclofenac.
AcenocoumarolAntipyrine may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Antipyrine.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Antipyrine.
Alendronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.
AliskirenAntipyrine may decrease the antihypertensive activities of Aliskiren.
AlprenololAntipyrine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Antipyrine.
AmikacinAntipyrine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideAntipyrine may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Antipyrine can be decreased when combined with Amiodarone.
AncrodAntipyrine may increase the anticoagulant activities of Ancrod.
Antithrombin III humanAntipyrine may increase the anticoagulant activities of Antithrombin III human.
ApixabanAntipyrine may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Apremilast.
AprepitantThe serum concentration of Antipyrine can be increased when it is combined with Aprepitant.
ArdeparinAntipyrine may increase the anticoagulant activities of Ardeparin.
ArgatrobanAntipyrine may increase the anticoagulant activities of Argatroban.
ArmodafinilThe metabolism of Antipyrine can be decreased when combined with Armodafinil.
ArotinololAntipyrine may decrease the antihypertensive activities of Arotinolol.
ArtemetherThe metabolism of Antipyrine can be decreased when combined with Artemether.
AtazanavirThe metabolism of Antipyrine can be decreased when combined with Atazanavir.
AtenololAntipyrine may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Antipyrine can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.
AzithromycinThe metabolism of Antipyrine can be decreased when combined with Azithromycin.
BalsalazideAntipyrine may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Antipyrine.
BecaplerminAntipyrine may increase the anticoagulant activities of Becaplermin.
BefunololAntipyrine may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Antipyrine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Benoxaprofen.
BetaxololAntipyrine may decrease the antihypertensive activities of Betaxolol.
BetaxololThe metabolism of Antipyrine can be decreased when combined with Betaxolol.
BevantololAntipyrine may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Antipyrine can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Antipyrine.
BisoprololAntipyrine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinAntipyrine may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Antipyrine can be decreased when combined with Boceprevir.
BopindololAntipyrine may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Antipyrine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Antipyrine can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.
BufuralolAntipyrine may decrease the antihypertensive activities of Bufuralol.
BumetanideAntipyrine may decrease the diuretic activities of Bumetanide.
BupranololAntipyrine may decrease the antihypertensive activities of Bupranolol.
BupropionThe metabolism of Antipyrine can be decreased when combined with Bupropion.
CaffeineThe metabolism of Antipyrine can be decreased when combined with Caffeine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Antipyrine.
CapecitabineThe metabolism of Antipyrine can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Antipyrine.
CarbamazepineThe metabolism of Antipyrine can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Antipyrine.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Antipyrine.
CarteololAntipyrine may decrease the antihypertensive activities of Carteolol.
CarvedilolAntipyrine may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Antipyrine.
CeliprololAntipyrine may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Antipyrine can be increased when it is combined with Ceritinib.
CertoparinAntipyrine may increase the anticoagulant activities of Certoparin.
ChloramphenicolThe metabolism of Antipyrine can be decreased when combined with Chloramphenicol.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Antipyrine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.
ChlorpromazineThe metabolism of Antipyrine can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Antipyrine.
CholecalciferolThe metabolism of Antipyrine can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Antipyrine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Antipyrine.
CimetidineThe metabolism of Antipyrine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Antipyrine can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Antipyrine can be decreased when combined with Citalopram.
Citric AcidAntipyrine may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Antipyrine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Antipyrine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Antipyrine can be decreased when combined with Clobazam.
ClodronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clodronate.
ClomipramineThe metabolism of Antipyrine can be decreased when combined with Clomipramine.
ClonixinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clonixin.
ClopidogrelThe metabolism of Antipyrine can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Antipyrine.
ClotrimazoleThe metabolism of Antipyrine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Antipyrine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Antipyrine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Antipyrine can be decreased when combined with Cocaine.
ColesevelamColesevelam can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Antipyrine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Antipyrine can be decreased when combined with Crizotinib.
CyclosporineAntipyrine may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Antipyrine can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Antipyrine can be decreased when it is combined with Cyproterone acetate.
D-LimoneneThe risk or severity of adverse effects can be increased when Antipyrine is combined with D-Limonene.
Dabigatran etexilateAntipyrine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.
DalteparinAntipyrine may increase the anticoagulant activities of Dalteparin.
DanaparoidAntipyrine may increase the anticoagulant activities of Danaparoid.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Antipyrine.
DarifenacinThe metabolism of Antipyrine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Antipyrine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Antipyrine can be increased when it is combined with Dasatinib.
DaunorubicinAntipyrine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Antipyrine can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Antipyrine is combined with Deferasirox.
DelavirdineThe metabolism of Antipyrine can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Antipyrine can be decreased when combined with Desipramine.
DesirudinAntipyrine may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.
DexamethasoneThe serum concentration of Antipyrine can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Antipyrine.
DextranAntipyrine may increase the anticoagulant activities of Dextran.
Dextran 40Antipyrine may increase the anticoagulant activities of Dextran 40.
Dextran 70Antipyrine may increase the anticoagulant activities of Dextran 70.
Dextran 75Antipyrine may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine.
DicoumarolAntipyrine may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Antipyrine.
DihydroergotamineThe metabolism of Antipyrine can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinAntipyrine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Antipyrine can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Antipyrine.
DiphenhydramineThe metabolism of Antipyrine can be decreased when combined with Diphenhydramine.
DisulfiramThe metabolism of Antipyrine can be decreased when combined with Disulfiram.
DoxorubicinAntipyrine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxorubicinThe metabolism of Antipyrine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Antipyrine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Antipyrine can be decreased when combined with Dronedarone.
DrospirenoneAntipyrine may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Droxicam.
DuloxetineThe metabolism of Antipyrine can be decreased when combined with Duloxetine.
Edetic AcidAntipyrine may increase the anticoagulant activities of Edetic Acid.
EdoxabanAntipyrine may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Antipyrine can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Antipyrine can be decreased when combined with Eliglustat.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Antipyrine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Antipyrine.
EnoxaparinAntipyrine may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Antipyrine is combined with Epirizole.
EpirubicinAntipyrine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneAntipyrine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.
ErythromycinThe metabolism of Antipyrine can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Antipyrine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololAntipyrine may decrease the antihypertensive activities of Esmolol.
EsomeprazoleThe metabolism of Antipyrine can be decreased when combined with Esomeprazole.
Etacrynic acidAntipyrine may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.
Ethyl biscoumacetateAntipyrine may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Antipyrine.
EtofenamateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.
EtravirineThe serum concentration of Antipyrine can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Antipyrine is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Antipyrine is combined with exisulind.
FelodipineThe metabolism of Antipyrine can be decreased when combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Antipyrine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Antipyrine.
FloxuridineThe metabolism of Antipyrine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Antipyrine can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flunixin.
FluorouracilThe metabolism of Antipyrine can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Antipyrine can be decreased when combined with Fluoxetine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Antipyrine.
FluvastatinThe metabolism of Antipyrine can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Antipyrine can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Antipyrine.
Fondaparinux sodiumAntipyrine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Antipyrine.
FosamprenavirThe metabolism of Antipyrine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Antipyrine can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Antipyrine.
FosphenytoinThe metabolism of Antipyrine can be increased when combined with Fosphenytoin.
FramycetinAntipyrine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideAntipyrine may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Antipyrine can be increased when it is combined with Fusidic Acid.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Antipyrine.
GemfibrozilThe metabolism of Antipyrine can be decreased when combined with Gemfibrozil.
GentamicinAntipyrine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.
HaloperidolThe metabolism of Antipyrine can be decreased when combined with Haloperidol.
HeparinAntipyrine may increase the anticoagulant activities of Heparin.
HirulogAntipyrine may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Antipyrine is combined with HMPL-004.
HydralazineAntipyrine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Antipyrine.
Hygromycin BAntipyrine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine.
IbuproxamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Antipyrine is combined with Icatibant.
IdarubicinAntipyrine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Antipyrine can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.
ImatinibThe metabolism of Antipyrine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Antipyrine can be decreased when combined with Imipramine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.
IndenololAntipyrine may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Antipyrine can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.
IndoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Antipyrine.
IsavuconazoniumThe metabolism of Antipyrine can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Antipyrine can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Isoxicam.
IsradipineThe metabolism of Antipyrine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Antipyrine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Antipyrine can be increased when it is combined with Ivacaftor.
KanamycinAntipyrine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Kebuzone.
KetoconazoleThe metabolism of Antipyrine can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Antipyrine.
LabetalolAntipyrine may decrease the antihypertensive activities of Labetalol.
LapatinibThe metabolism of Antipyrine can be decreased when combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Antipyrine.
LepirudinAntipyrine may increase the anticoagulant activities of Lepirudin.
LevobunololAntipyrine may decrease the antihypertensive activities of Levobunolol.
LidocaineThe metabolism of Antipyrine can be decreased when combined with Lidocaine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Antipyrine.
LithiumThe serum concentration of Lithium can be increased when it is combined with Antipyrine.
LopinavirThe metabolism of Antipyrine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Antipyrine can be decreased when combined with Lorcaserin.
LornoxicamThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Antipyrine.
LovastatinThe metabolism of Antipyrine can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Antipyrine.
LuliconazoleThe serum concentration of Antipyrine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Antipyrine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Antipyrine can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Antipyrine.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Antipyrine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Antipyrine.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.
MesalazineAntipyrine may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Antipyrine.
MetamizoleThe risk or severity of adverse effects can be increased when Antipyrine is combined with Metamizole.
MethadoneThe metabolism of Antipyrine can be decreased when combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Antipyrine.
MethotrimeprazineThe metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.
MetipranololAntipyrine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.
MetoprololAntipyrine may decrease the antihypertensive activities of Metoprolol.
MetoprololThe metabolism of Antipyrine can be decreased when combined with Metoprolol.
MetrizamideAntipyrine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe metabolism of Antipyrine can be decreased when combined with Mexiletine.
MifepristoneThe metabolism of Antipyrine can be decreased when combined with Mifepristone.
MirabegronThe metabolism of Antipyrine can be decreased when combined with Mirabegron.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Antipyrine.
MitotaneThe serum concentration of Antipyrine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Antipyrine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Antipyrine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Antipyrine.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Antipyrine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Antipyrine.
NadololAntipyrine may decrease the antihypertensive activities of Nadolol.
NadroparinAntipyrine may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Antipyrine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Antipyrine.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine.
NCX 4016The risk or severity of adverse effects can be increased when Antipyrine is combined with NCX 4016.
NefazodoneThe metabolism of Antipyrine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Antipyrine can be decreased when combined with Nelfinavir.
NeomycinAntipyrine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nepafenac.
NetilmicinAntipyrine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Antipyrine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Antipyrine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Antipyrine can be decreased when combined with Nicardipine.
NicotineThe metabolism of Antipyrine can be decreased when combined with Nicotine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.
NilotinibThe metabolism of Antipyrine can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Antipyrine.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Antipyrine.
OlaparibThe metabolism of Antipyrine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Antipyrine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.
OlsalazineAntipyrine may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Antipyrine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Antipyrine.
OmeprazoleThe metabolism of Antipyrine can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Orgotein.
OsimertinibThe serum concentration of Antipyrine can be increased when it is combined with Osimertinib.
OtamixabanAntipyrine may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.
OxprenololAntipyrine may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oxyphenbutazone.
PalbociclibThe serum concentration of Antipyrine can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.
PanobinostatThe metabolism of Antipyrine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Antipyrine can be decreased when combined with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Antipyrine is combined with Parecoxib.
ParomomycinAntipyrine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe metabolism of Antipyrine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololAntipyrine may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Antipyrine can be increased when combined with Pentobarbital.
Pentosan PolysulfateAntipyrine may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Antipyrine.
PhenindioneAntipyrine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Antipyrine can be increased when combined with Phenobarbital.
PhenprocoumonAntipyrine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Antipyrine.
PhenytoinThe metabolism of Antipyrine can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.
PindololAntipyrine may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Antipyrine can be decreased when combined with Pioglitazone.
PiretanideAntipyrine may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.
PlicamycinAntipyrine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Antipyrine.
PosaconazoleThe metabolism of Antipyrine can be decreased when combined with Posaconazole.
PractololAntipyrine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Antipyrine.
PrilocaineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prilocaine.
PrimidoneThe metabolism of Antipyrine can be increased when combined with Primidone.
ProbenecidThe serum concentration of Antipyrine can be increased when it is combined with Probenecid.
PromazineThe metabolism of Antipyrine can be decreased when combined with Promazine.
PropacetamolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Propacetamol.
PropranololAntipyrine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Antipyrine.
Protein CAntipyrine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeAntipyrine may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Antipyrine is combined with PTC299.
PuromycinAntipyrine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Antipyrine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Antipyrine can be increased when it is combined with Quazepam.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Antipyrine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Antipyrine.
QuinidineThe metabolism of Antipyrine can be decreased when combined with Quinidine.
QuinineThe metabolism of Antipyrine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Antipyrine can be decreased when combined with Rabeprazole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Antipyrine.
RanolazineThe metabolism of Antipyrine can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Antipyrine.
ResveratrolThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.
ReviparinAntipyrine may increase the anticoagulant activities of Reviparin.
RibostamycinAntipyrine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Antipyrine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Antipyrine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Antipyrine can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.
RitonavirThe metabolism of Antipyrine can be decreased when combined with Ritonavir.
RivaroxabanAntipyrine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Antipyrine.
RolapitantThe metabolism of Antipyrine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Antipyrine can be decreased when combined with Ropinirole.
RosiglitazoneThe metabolism of Antipyrine can be decreased when combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Antipyrine.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Antipyrine.
SaquinavirThe metabolism of Antipyrine can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Antipyrine.
SecobarbitalThe metabolism of Antipyrine can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Seratrodast.
SertralineThe metabolism of Antipyrine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Antipyrine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Antipyrine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Antipyrine can be increased when it is combined with Simeprevir.
Sodium NitriteThe risk or severity of adverse effects can be increased when Antipyrine is combined with Sodium Nitrite.
SorafenibThe metabolism of Antipyrine can be decreased when combined with Sorafenib.
SotalolAntipyrine may decrease the antihypertensive activities of Sotalol.
SpectinomycinAntipyrine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Antipyrine.
SpironolactoneAntipyrine may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Antipyrine is combined with SRT501.
St. John's WortThe serum concentration of Antipyrine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Antipyrine can be increased when it is combined with Stiripentol.
StreptomycinAntipyrine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinAntipyrine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Antipyrine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Antipyrine can be decreased when combined with Sulfamethoxazole.
SulfasalazineAntipyrine may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antipyrine.
SulfisoxazoleThe metabolism of Antipyrine can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Antipyrine.
SulodexideAntipyrine may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.
TacrolimusAntipyrine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Antipyrine.
TamoxifenThe metabolism of Antipyrine can be decreased when combined with Tamoxifen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Antipyrine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Antipyrine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Antipyrine can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Antipyrine.
TenofovirThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tenofovir.
TenofovirThe metabolism of Antipyrine can be decreased when combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Antipyrine.
TepoxalinThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tepoxalin.
TerbinafineThe metabolism of Antipyrine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Antipyrine is combined with Teriflunomide.
TheophyllineThe metabolism of Antipyrine can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Antipyrine.
ThioridazineThe metabolism of Antipyrine can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Antipyrine can be decreased when combined with Thiotepa.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Antipyrine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Antipyrine can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiludronate.
TimololAntipyrine may decrease the antihypertensive activities of Timolol.
TipranavirThe metabolism of Antipyrine can be decreased when combined with Tipranavir.
TobramycinAntipyrine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Antipyrine can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.
TopiramateThe metabolism of Antipyrine can be decreased when combined with Topiramate.
TorasemideAntipyrine may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Antipyrine.
TranilastThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tranilast.
TranylcypromineThe metabolism of Antipyrine can be decreased when combined with Tranylcypromine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.
TriamtereneAntipyrine may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Antipyrine.
TrimethoprimThe metabolism of Antipyrine can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Antipyrine.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Antipyrine.
Valproic AcidThe metabolism of Antipyrine can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Antipyrine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Antipyrine.
VemurafenibThe serum concentration of Antipyrine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Antipyrine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Antipyrine can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Antipyrine can be decreased when combined with Voriconazole.
WarfarinAntipyrine may increase the anticoagulant activities of Warfarin.
XimelagatranAntipyrine may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Antipyrine can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Antipyrine.
ZiprasidoneThe metabolism of Antipyrine can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. [PubMed:11695253 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. [PubMed:11695253 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996 Jun;59(6):613-23. [PubMed:8681486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94. [PubMed:8801065 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on July 26, 2007 04:19 / Updated on August 17, 2016 12:23